|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.6 CHF | -0.69% |
|
+0.28% | +40.67% |
| Apr. 26 | Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 | CI |
| Apr. 25 | Cosmo Pharmaceuticals Names New CEO, Chairman | MT |
Cosmo Pharmaceuticals N.V. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 96.72 million compared to EUR 102.09 million a year ago. Net income was EUR 1.15 million compared to EUR 17.23 million a year ago.
Basic earnings per share from continuing operations was EUR 0.071 compared to EUR 1.049 a year ago. Diluted earnings per share from continuing operations was EUR 0.071 compared to EUR 1.049 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +40.67% | 1.26B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
COSMO PHARMACEUTICALS N.V. 
